Beyond PARP—POLθ as an anticancer target-Reference-Cited by-同舟云学术

Beyond PARP—POLθ as an anticancer target

Published:2018-03-16 Issue:6381 Volume:359 Page:1217-1218
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Higgins Geoff S.¹,Boulton Simon J.²³

Affiliation:

1. Cancer Research UK–Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.

2. The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

3. Artios Pharma Limited, Maia, Babraham Research Campus, Cambridge CB22 3AT, UK.

Abstract

Targeting cancers dependent on DNA polymerase θ has considerable clinical potential

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference14 articles.

1. When Genome Maintenance Goes Badly Awry

2. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

3. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

4. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

5. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural Basis for Polθ-Helicase DNA Binding and Microhomology-Mediated End-Joining;2024-06-07

2. Long‐lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID‐19 vaccination;Pharmacology Research & Perspectives;2024-06

3. Overexpression of human DNA polymerase theta is a biomarker of aggressive and DNA repair-deficient papillary thyroid cancers;Surgery;2024-06

4. Melanoma-Derived DNA Polymerase Theta Variants Exhibit Altered DNA Polymerase Activity;Biochemistry;2024-04-26

5. Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors;Journal of Medicinal Chemistry;2024-02-20